Welcome to our dedicated page for Finance Of America Companies SEC filings (Ticker: FOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the financial ripple effects of home-equity conversion mortgages and capital-markets hedges in Finance Of America Companies’ filings can feel daunting. Each new Finance Of America Companies quarterly earnings report 10-Q filing spans dense mortgage accounting. Investors often search for Finance Of America Companies SEC filings explained simply, especially when loan fair-value marks shift quickly.
Stock Titan solves this complexity. Our AI reads every submission the moment it hits EDGAR and delivers clear highlights. Need to monitor Finance Of America Companies insider trading Form 4 transactions? We stream Finance Of America Companies Form 4 insider transactions real-time, flagging option grants and reverse-mortgage segment share sales. Earnings tables, liquidity ratios, and risk disclosures are summarised so you can focus on decisions, not digging through PDFs.
Use the filters below to jump straight to what matters:
- Finance Of America Companies annual report 10-K simplified – uncover segment profit drivers and servicing rights valuations.
- Finance Of America Companies proxy statement executive compensation – compare incentive pay with loan production targets.
- Finance Of America Companies 8-K material events explained – see how rate moves or warehouse-line amendments affect liquidity.
- Finance Of America Companies earnings report filing analysis – AI detects quarter-over-quarter trends in funded volume and net interest margin.
- Guidance on understanding Finance Of America Companies SEC documents with AI – step-by-step walkthroughs for deeper modelling.
Whether you’re evaluating mortgage servicing valuations, monitoring Finance Of America Companies executive stock transactions Form 4, or benchmarking retirement-solution growth, our platform keeps you current with real-time alerts and expert context.
Intellia Therapeutics (NTLA) has filed a Form 4 reporting that Vice President & Chief Accounting Officer Michael P. Dube sold 2,503 shares of common stock on 07/02/2025 at $9.95 per share. The filing states this was a mandatory sell-to-cover transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs) on 07/01/2025, rather than a discretionary sale. After the transaction, Dube continues to hold 57,137 shares directly. No derivative positions were reported.
The dollar value of the sale (≈ $25 k) is immaterial relative to Intellia’s market capitalization and daily trading volume, and the officer retains a meaningful equity stake. As such, investors are likely to view the disclosure as routine housekeeping with neutral implications for the stock’s fundamental outlook.